Keryx Biopharmaceuticals (KERX) Is Today's Roof Leaker Stock
at The Street - Tue Sep 09, 12:34PM CDT
Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Nasdaq stocks posting largest percentage decreases
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Most active Nasdaq-traded stocks
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma
PR Newswire - Tue Sep 09, 8:10AM CDT
On Monday, September 8, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average declined 0.15%, to finish the day at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index also advancing 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Sangamo BioSciences Inc. (NASDAQ:SGMO), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free research on these five companies can be accessed at:
Downgrade Alert for Keryx Biopharmaceuticals (KERX)
Comtex SmarTrend(R) - Tue Sep 09, 8:04AM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) was downgraded from Market Perform to Underperform at FBR Capital today. The stock closed yesterday at $15.11 on volume of 13.3 million shares, above average daily volume of 1.7 million. Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.
Market Maker Surveillance Report. GT, KERX, CPE, AXAS, MNGGF, KMDA, Losing Stocks With Lowest Price Friction For Monday, September 8th 2014
M2 - Tue Sep 09, 3:28AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4710 companies with "abnormal" market making, 2110 companies with positive Friction Factors and 2786 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. The Goodyear Tire & Rubber Co (NYSE:GT), Keryx Biopharmaceuticals Inc (NASDAQ:KERX), Callon Petroleum Co (NYSE:CPE), Abraxas Petroleum Corp (NASDAQ:AXAS), (OTC:MNGGF), (NASDAQ:KMDA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:05PM CDT
The FDA has approved Keryx's (KERX) ferric citrate to control serum phosphorus levels in patients suffering from CKD on dialysis.
Why Keryx Biopharmaceuticals Stock Plunged
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 08, 1:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Keryx Biopharmaceuticals , a...
Silver Spring Networks Starts The Week Strong
at The Street - Mon Sep 08, 12:30PM CDT
Silver Spring Networks Inc (NYSE:SSNI), Essent Group Ltd (NYSE:ESNT) and LipoScience Inc (NASDAQ:LPDX) are today's top-gaining billionaire stock picks midday. Having a tough start to the week are ...
Why Keryx Biopharmaceuticals (KERX) Stock Is Falling Today
at The Street - Mon Sep 08, 10:25AM CDT
Keryx Biopharmaceuticals (KERX) shares are declining after being downgraded to 'underperform' by analysts at FBR Capital on Monday.
Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:55AM CDT
Keryx Biopharmaceuticals has been witnessing a negative trend in its earnings estimate front and possess an unfavorable Zacks Rank #4 (Sell)
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label
at The Street - Mon Sep 08, 6:00AM CDT
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Keryx Biopharmaceuticals wins US FDA approval for ferric citrate for dialysis patients with hyperphosphatemia
M2 - Mon Sep 08, 4:25AM CDT
Renal therapy company Keryx Biopharmaceuticals (NasdaqCM:KERX) disclosed on Friday the receipt of approval from the US Food and Drug Administration (FDA) for Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Correction: Keryx-Drug Approval story
AP - Sat Sep 06, 8:01AM CDT
NEW YORK (AP) — In a Sept. 5 story about a new drug from Keryx Biopharmaceuticals, The Associated Press misstated the timing of the company's stock movement. The stock had been falling before the FDA drug approval announcement was made.
Keryx Biopharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 5.45%
Comtex SmarTrend(R) - Fri Sep 05, 3:49PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $14.80 to a high of $18.01. Yesterday, the shares fell 5.4%, which took the trading range below the 3-day low of $17.85 on volume of 15.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Fri Sep 05, 3:00PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 16 Annual Global Investment Conference to be held from September 8-10, 2014 at the New York Palace Hotel in New York City.
Infoblox Inc. (BLOX) Climbs On Earnings
at The Street - Fri Sep 05, 1:49PM CDT
Infoblox Inc. (NYSE:BLOX), Yandex NV (NASDAQ:YNDX) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) surged early in the day today, while Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Repros Ph...